Zur Kurzanzeige

dc.creatorBeltsios E.T., Mavrovounis G., Adamou A., Panagiotopoulos N.en
dc.date.accessioned2023-01-31T07:37:52Z
dc.date.available2023-01-31T07:37:52Z
dc.date.issued2021
dc.identifier10.1007/s11748-020-01549-2
dc.identifier.issn18636705
dc.identifier.urihttp://hdl.handle.net/11615/71543
dc.description.abstractObjective: Malignant pleural effusion is a severe and common complication in patients with primary or metastatic malignancies of the pleura. Although talc pleurodesis is widely used for managing malignant pleural effusions, there is still controversy in the literature regarding its superiority compared to other approaches. We conducted this meta-analysis to further investigate its efficacy compared to alternative interventions. Methods: We systematically reviewed the PubMed, Cochrane, and Scopus databases to identify studies that fulfilled our inclusion criteria. Study quality was evaluated using validated tools and the pooled Risk Ratio (RR) and confidence interval (CI) were calculated. We performed sensitivity analyses based on the meta-analysis method and type of study. Results: Twenty-four studies were included in the current systematic review meta-analysis. Talc pleurodesis was associated with statistically significant higher successful pleurodesis rates when compared with all controls [RR (95% CI) 1.15 (1.00, 1.31); Pz = 0.04], only chemical controls [RR (95% CI) 1.26 (1.13, 1.40); Pz < 0.0001], and bleomycin [RR (95% CI) 1.22 (1.05, 1.42); Pz = 0.008]. The comparison between talc pleurodesis and controls at the > 1-month follow-up time point favored talc pleurodesis [RR (95% CI): 1.62 (1.15, 2.27); Pz = 0.005]. Finally, talc poudrage was associated with a statistically significant higher successful pleurodesis rate when compared with all controls. Sensitivity analyses verified the robustness of our results. Conclusion: Talc pleurodesis is an effective MPE management approach presenting borderline statistically significant superiority compared to control methods especially compared to bleomycin as well as when pleurodesis success is evaluated later than 1 month postoperatively. © 2020, The Japanese Association for Thoracic Surgery.en
dc.language.isoenen
dc.sourceGeneral Thoracic and Cardiovascular Surgeryen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85096373144&doi=10.1007%2fs11748-020-01549-2&partnerID=40&md5=6ed8d86a06d9e5a4ad1a3f02e3b97cc6
dc.subjectbleomycinen
dc.subjectchlormethineen
dc.subjectdoxycyclineen
dc.subjectpovidone iodineen
dc.subjectsilver nitrateen
dc.subjecttalcen
dc.subjecttetracyclineen
dc.subjectbleomycinen
dc.subjecttalcen
dc.subjectadulten
dc.subjectArticleen
dc.subjectblood autotransfusionen
dc.subjectcohort analysisen
dc.subjectdisease associationen
dc.subjectfollow upen
dc.subjecthumanen
dc.subjectmalignant pleura effusionen
dc.subjectMantel Haenszel testen
dc.subjectmeta analysisen
dc.subjectNewcastle-Ottawa scaleen
dc.subjectpleurodesisen
dc.subjectprospective studyen
dc.subjectsystematic reviewen
dc.subjectthorax drainageen
dc.subjectvideo assisted thoracoscopic surgeryen
dc.subjectmalignant pleura effusionen
dc.subjectpleurodesisen
dc.subjectBleomycinen
dc.subjectHumansen
dc.subjectPleural Effusion, Malignanten
dc.subjectPleurodesisen
dc.subjectTalcen
dc.subjectSpringer Japanen
dc.titleTalc pleurodesis in malignant pleural effusion: a systematic review and meta-analysisen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige